CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.
Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|B-cell Prolymphocytic Leukemia|Diffuse Large Cell Lymphoma
BIOLOGICAL: PCAR-019 (anti-CD19 CAR-T cells)
Phase I: Adverse events attributed to the administration of the anti-CD19 CAR-T cells, 2 years
Phase II: Objective Response Rate, Safety follow-up is 100 days from last CAR-T infusion.
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.